“In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of 3.2% in low-risk controls and 15.6% in high-risk controls.”

0.9908 under ledger-default@0.3.0 at snapshot 27745.

What was asked, and where it stands. Provisional until audited.

Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (1 claim, 4 checks)

Share:

Checked in Galedra: score 0.99, strongly supported · not yet reviewed by anyone else “In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of 3.2% in low-risk controls and 15.6% in…” https://galedra.org/investigations/01a0eae1-bc75-7c37-a006-4a53181c3c5e

“In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of 3.2% in low-risk controls and 15.6% in high-risk controls.”

Supported · 0.9908 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card